qSARS-CoV-2 IgG/IgM Rapid Test

A Medical company "Mayamed" offers Covid-19 fast tests of Cellex SARS-CoV-2. Cellex is a manufacturer of high quality rapid tests in the US market, which has an international and world-recognized ISO standard, CE mark and FDA certification.

The Cellex qSARS-CoV-2 IgG/IgM Rapid Test is a lateral flow immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in serum, plasma (EDTA, citrate) or venipuncture whole blood specimens from patients suspected of COVID-19 infection by a healthcare provider;

The qSARS-CoV-2 IgG/IgM Rapid Test is an aid in the diagnosis of patients with suspected SARS-CoV-2 infection in conjunction with clinical presentation and the results of other laboratory tests;

Results from the qSARS-CoV-2 IgG/IgM Rapid Test should not be used as the sole basis for diagnosis.

Sensitivity - 94%, Specifity - 97%